leflunomide has been researched along with 2019 Novel Coronavirus Disease in 14 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recurrences of COVID-19 were observed in a patient with long-term usage of hydroxychloroquine, leflunomide, and glucocorticoids due to her 30-year history of rheumatoid arthritis (RA)." | 5.05 | A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab. ( Cai, S; Dong, L; Li, M; Sun, W, 2020) |
| "A case with rheumatoid arthritis and insufficient compensation under disease-modifying combined long-term therapy with methotrexate and leflunomide is reported." | 3.96 | [Biological therapy after COVID-19 infection : No reactivation of a COVID-19 infection with positive SARS-CoV-2 antibody status under biological therapy]. ( Lange, U; Müller-Ladner, U; Steinchen, N, 2020) |
| "Treatment with leflunomide was not associated with a difference from the interferon-alone group in the duration of viral shedding (hazard ratio for negative reverse-transcription PCR, 0." | 3.01 | Treatment of Coronavirus Disease 2019 Patients With Prolonged Postsymptomatic Viral Shedding With Leflunomide: A Single-center Randomized Controlled Clinical Trial. ( Hu, K; Hu, W; Li, X; Liu, Z; Lu, L; Wan, Z; Wang, M; Wang, T; Zeng, S; Zhang, Y; Zhao, D; Zhao, Y; Zheng, Z, 2021) |
| "Treatment with leflunomide or low doses of glucocorticoids were not associated with severe course in our cohort." | 2.82 | COVID-19 among patients with giant cell arteritis: a single-centre observational study from Slovenia. ( Hočevar, A; Ješe, R; Kramarič, J; Rotar, Ž; Tomšič, M, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 14 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Raghuvanshi, R | 1 |
| Bharate, SB | 1 |
| Kramarič, J | 1 |
| Ješe, R | 1 |
| Tomšič, M | 1 |
| Rotar, Ž | 1 |
| Hočevar, A | 1 |
| Auroux, M | 1 |
| Laurent, B | 1 |
| Coste, B | 1 |
| Massy, E | 1 |
| Mercier, A | 1 |
| Durieu, I | 1 |
| Confavreux, CB | 1 |
| Lega, JC | 1 |
| Mainbourg, S | 1 |
| Coury, F | 1 |
| Marques, CDL | 3 |
| Ribeiro, SLE | 3 |
| Albuquerque, CP | 3 |
| de Sousa Studart, SA | 3 |
| Ranzolin, A | 3 |
| de Andrade, NPB | 3 |
| Dantas, AT | 3 |
| Mota, GD | 3 |
| Resende, GG | 3 |
| Marinho, AO | 3 |
| Angelieri, D | 3 |
| Andrade, D | 3 |
| Ribeiro, FM | 3 |
| Omura, F | 3 |
| Silva, NA | 3 |
| Rocha Junior, L | 3 |
| Brito, DE | 3 |
| Fernandino, DC | 3 |
| Yazbek, MA | 3 |
| Souza, MPG | 3 |
| Ximenes, AC | 3 |
| Martins, ASS | 3 |
| Castro, GRW | 3 |
| Oliveira, LC | 3 |
| Freitas, ABSB | 3 |
| Kakehasi, AM | 3 |
| Gomides, APM | 3 |
| Reis Neto, ET | 3 |
| Pileggi, GS | 3 |
| Ferreira, GA | 3 |
| Mota, LMH | 3 |
| Xavier, RM | 3 |
| de Medeiros Pinheiro, M | 3 |
| Barrett, R | 2 |
| Lin, SX | 1 |
| Culliford, D | 1 |
| Fraser, S | 1 |
| Edwards, CJ | 1 |
| Kralj-Hans, I | 1 |
| Li, K | 1 |
| Wesek, A | 1 |
| Lamorgese, A | 1 |
| Omar, F | 1 |
| Ranasinghe, K | 1 |
| McGee, M | 1 |
| Brack, K | 1 |
| Li, S | 2 |
| Aggarwal, R | 1 |
| Bulle, A | 1 |
| Kodre, A | 1 |
| Sharma, S | 1 |
| Fluck, D | 1 |
| John, I | 1 |
| Sharma, P | 1 |
| Belsey, JD | 1 |
| Li, L | 1 |
| Seshasai, SRK | 1 |
| Li, HL | 1 |
| Marczin, N | 1 |
| Chen, Z | 1 |
| Steinchen, N | 1 |
| Müller-Ladner, U | 1 |
| Lange, U | 1 |
| Cai, S | 1 |
| Sun, W | 1 |
| Li, M | 1 |
| Dong, L | 1 |
| Hu, K | 3 |
| Wang, M | 3 |
| Zhao, Y | 3 |
| Zhang, Y | 2 |
| Wang, T | 2 |
| Zheng, Z | 2 |
| Li, X | 2 |
| Zeng, S | 2 |
| Zhao, D | 2 |
| Li, H | 2 |
| Xu, K | 2 |
| Lan, K | 2 |
| Coelho, AR | 1 |
| Oliveira, PJ | 1 |
| Xiong, R | 1 |
| Zhang, L | 1 |
| Sun, Y | 1 |
| Ding, M | 1 |
| Wang, Y | 1 |
| Wu, Y | 1 |
| Shang, W | 1 |
| Jiang, X | 1 |
| Shan, J | 1 |
| Shen, Z | 1 |
| Tong, Y | 1 |
| Xu, L | 1 |
| Chen, Y | 1 |
| Liu, Y | 1 |
| Zou, G | 1 |
| Lavillete, D | 1 |
| Zhao, Z | 1 |
| Wang, R | 1 |
| Zhu, L | 1 |
| Xiao, G | 1 |
| Hu, W | 1 |
| Liu, Z | 1 |
| Lu, L | 1 |
| Wan, Z | 1 |
| DeVito, NJ | 1 |
3 reviews available for leflunomide and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
COVID-19 among patients with giant cell arteritis: a single-centre observational study from Slovenia.
Topics: Cardiovascular Diseases; COVID-19; Giant Cell Arteritis; Glucocorticoids; Humans; Hypertension; Lefl | 2022 |
Serological response to SARS-CoV-2 vaccination in patients with inflammatory rheumatic disease treated with disease modifying anti-rheumatic drugs: A cohort study and a meta-analysis.
Topics: Abatacept; Adult; Aged; Antirheumatic Agents; Cohort Studies; COVID-19; COVID-19 Vaccines; Humans; I | 2022 |
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab.
Topics: Aged; Anti-Bacterial Agents; Antifungal Agents; Antirheumatic Agents; Antiviral Agents; Arthritis, R | 2020 |
3 trials available for leflunomide and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Leflunomide treatment for patients hospitalised with COVID-19: DEFEAT-COVID randomised controlled trial.
Topics: Adult; Aged; COVID-19; Female; Humans; Leflunomide; Male; Middle Aged; Oxygen; Prospective Studies; | 2023 |
A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial.
Topics: Aged; Antiviral Agents; C-Reactive Protein; China; COVID-19; COVID-19 Drug Treatment; Female; Humans | 2020 |
Treatment of Coronavirus Disease 2019 Patients With Prolonged Postsymptomatic Viral Shedding With Leflunomide: A Single-center Randomized Controlled Clinical Trial.
Topics: Adult; Antiviral Agents; COVID-19; Dihydroorotate Dehydrogenase; Humans; Leflunomide; Prospective St | 2021 |
8 other studies available for leflunomide and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Through | 2022 |
COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-Brasil cross-sectional data.
Topics: Arthritis, Psoriatic; Brazil; COVID-19; Cross-Sectional Studies; Humans; Leflunomide; Middle Aged; P | 2022 |
COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-Brasil cross-sectional data.
Topics: Arthritis, Psoriatic; Brazil; COVID-19; Cross-Sectional Studies; Humans; Leflunomide; Middle Aged; P | 2022 |
COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-Brasil cross-sectional data.
Topics: Arthritis, Psoriatic; Brazil; COVID-19; Cross-Sectional Studies; Humans; Leflunomide; Middle Aged; P | 2022 |
COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-Brasil cross-sectional data.
Topics: Arthritis, Psoriatic; Brazil; COVID-19; Cross-Sectional Studies; Humans; Leflunomide; Middle Aged; P | 2022 |
COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-Brasil cross-sectional data.
Topics: Arthritis, Psoriatic; Brazil; COVID-19; Cross-Sectional Studies; Humans; Leflunomide; Middle Aged; P | 2022 |
COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-Brasil cross-sectional data.
Topics: Arthritis, Psoriatic; Brazil; COVID-19; Cross-Sectional Studies; Humans; Leflunomide; Middle Aged; P | 2022 |
COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-Brasil cross-sectional data.
Topics: Arthritis, Psoriatic; Brazil; COVID-19; Cross-Sectional Studies; Humans; Leflunomide; Middle Aged; P | 2022 |
COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-Brasil cross-sectional data.
Topics: Arthritis, Psoriatic; Brazil; COVID-19; Cross-Sectional Studies; Humans; Leflunomide; Middle Aged; P | 2022 |
COVID-19 was not associated or trigger disease activity in spondylarthritis patients: ReumaCoV-Brasil cross-sectional data.
Topics: Arthritis, Psoriatic; Brazil; COVID-19; Cross-Sectional Studies; Humans; Leflunomide; Middle Aged; P | 2022 |
Impact of the COVID-19 pandemic on prescription refills for immune-mediated inflammatory disorders: a time series analysis (January 2019 to January 2021) using the English Prescribing Dataset.
Topics: Azathioprine; Communicable Disease Control; COVID-19; Drug Prescriptions; Humans; Hydroxychloroquine | 2022 |
[Biological therapy after COVID-19 infection : No reactivation of a COVID-19 infection with positive SARS-CoV-2 antibody status under biological therapy].
Topics: Antibodies, Viral; Arthritis, Rheumatoid; Betacoronavirus; Biological Therapy; Coronavirus Infection | 2020 |
Dihydroorotate dehydrogenase inhibitors in SARS-CoV-2 infection.
Topics: Antiviral Agents; Betacoronavirus; Biphenyl Compounds; Coronavirus Infections; COVID-19; COVID-19 Dr | 2020 |
Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
Topics: Animals; Antiviral Agents; Betacoronavirus; Binding Sites; Cell Line; Coronavirus Infections; COVID- | 2020 |
Concerning Trials Registration.
Topics: COVID-19; Humans; Leflunomide; Registries; SARS-CoV-2; Virus Shedding | 2021 |
Reply to DeVito.
Topics: COVID-19; Humans; Leflunomide; SARS-CoV-2; Virus Shedding | 2021 |